Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results

By Dominic Chopping

Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy weight-loss drug.

The Danish pharmaceutical giant said that despite U.S. regulators ordering an end to the practice known as compounding, it has continued, with multiple entities still marketing and selling unbranded versions of its drug.

Competition and slower sales growth of its Ozempic diabetes drug in the U.S. also dragged on its results, the company said.

Write to Dominic Chopping at dominic.chopping@wsj.com